November 29th is China Dream Day. It means "everyone can write dreams and create the future." Did you have a childhood dream that you particularly wanted to realize? For example, it would be great if there was a specific drug for my grandma’s Alzheimer’s disease; it would be grea

November 29th is China Dream Day. It means "everyone can write dreams and create the future." Did you have a childhood dream that you particularly wanted to realize? For example, it would be great if there was a specific drug for my grandma’s Alzheimer’s disease; it would be great if I could put on Doraemon’s bamboo dragonfly and go directly from home to school; what if… the reporter takes you into Nanjing’s cutting-edge high-tech companies , and explore together the dreams that are being realized. Find out which scenes you imagined when you were a child.

Focusing on the research and development of new drugs for stroke and Alzheimer’s disease, Nanjing’s “unicorn” has brought hope to countless patients.

Recently, Nanjing Ningdan New Drug Technology Co., Ltd. officially announced the completion of several hundred million yuan in Series C financing. "After a stroke, about 1.9 million neurons die every minute. The longer the delay, the greater the risk of disability. The golden time for treatment is extremely precious." Dr. Chen Rong, deputy general manager of Ningdan New Drugs, told reporters that stroke also Stroke, as everyone calls it, has become a major disease threatening public health. There are 4 million new stroke patients in my country every year. However, the traditional process of onset, hospitalization and professional treatment often causes patients to miss the best opportunity for rescue. Xianbixin® sublingual tablets developed by Ningdan New Drug and Simcere Pharmaceuticals are aimed at this problem. It uses the first sublingual administration method to supplement the existing intravenous drip brain protective agents to achieve the purpose of full-process stroke treatment. It not only solves the problem of dysphagia that stroke patients may have during acute onset, but also allows patients to receive timely treatment at home or on the way to the hospital, thereby significantly shortening treatment time and reducing the risk of condition deterioration. At present, this new drug has been applied for marketing and has been designated as a "breakthrough therapy" by the US FDA.

Alzheimer's disease is another global medical problem, and there is currently no drug that can completely cure it. Existing treatment options mostly focus on relieving symptoms, but are difficult to delay the course of the disease. The y-1 project developed by Ningdan New Drug has now entered the clinical stage and is expected to open up new paths for the treatment of intracranial tumors and Alzheimer's disease. Chen Rong introduced that the drug was developed based on the internationally cutting-edge trpml-1 ion channel target and is expected to fundamentally delay the disease process by clearing harmful proteins in neurons such as hyperphosphorylated tau protein.

took a "flight" to go to work, how is the progress now?

At the recently held first China (Shaoxing) Low Altitude Economic Exhibition, Evit (Nanjing) Aviation Technology Co., Ltd. located in Yuhuatai District unveiled the 2-ton EVTOL-ET9 for the first time. The et9 can accommodate five passengers, has a maximum take-off weight of 2,200 kilograms, a design cruising speed of 240 kilometers per hour, and a maximum range of 240 kilometers, which greatly satisfies people's yearning for quick travel.

evtol-et9 prototype test flight Picture source: Evit

et9 prototype is a composite wing configuration with a wingspan of about 14 meters. It is compact and flexible and easy to take off and land. In the future, it can take off and land in some buildings and a playground. Moreover, it can be charged using a charging pile, which is more convenient than helicopter refueling. It will be widely used in high-frequency freight, special tourism, emergency rescue, urban air travel and other scenarios. "In the future, as long as there is a platform similar to a 'bus stop' as a take-off and landing point, citizens can take a 'flying' to go where they want to go." Co-founder and deputy general manager Zhang Benling said that next, the et9 prototype will Carry out continuous test flights, connect with airworthiness authorities, and enter the airworthiness verification process. The main enterprise series products are expected to be launched on the market in the next two to three years.

"Human iPSC cardiomyocyte injection" has been approved by China and the United States, and is expected to bring revolutionary treatment options to heart failure patients

In recent years, the incidence of breast cancer has been increasing and younger. The entrepreneurial team of Nanjing Xinke Medical Device Co., Ltd. finally ushered in the "dawn" in January this year - its independently developed breast tissue marker product obtained the third-class medical device registration certificate issued by the State Food and Drug Administration. The first Class III domestic medical device certificate in the industry, filling a domestic gap.

This product consists of a push tool, a puncture needle and a marker. The marker is set in the puncture needle.Under the operation of the technician, the marker is punctured into the breast simulator. After reaching the edge of the lesion, the button on the push tool is pressed, and the marker is released at the edge of the lesion.

The operation process of using breast tissue markers (picture from Xinke Medical)

is made of special metal and polymer materials. Several breast tissue markers, which are about the same size as the tip of a syringe pen, are implanted into the tumor through image-guided puncture. The edge is set as a reference object at the edge of the tumor. After neoadjuvant treatment of tumors, doctors can accurately identify changes in treatment effects with the help of breast tissue markers and imaging technology.

In addition, the breast tissue marker product independently developed by the entrepreneurial team of Nanjing Xinke Medical Device Co., Ltd. has obtained the Class III medical device registration certificate issued by the State Food and Drug Administration. It is the first Class III domestic medical device in the industry. certificate, filling the domestic gap. The product consists of a pushing tool, a puncture needle tube and a marker, and the marker is set in the puncture needle tube. Under the operation of the technician, the marker is punctured into the breast simulator. After reaching the edge of the lesion, the button on the push tool is pressed, and the marker is released at the edge of the lesion.

In addition to being used in breast-conserving surgery under neoadjuvant treatment, breast tissue markers also have two application scenarios. One is to place markers after biopsy of suspected breast cancer, which can avoid repeated biopsies and follow-up treatment; the other is to Breast tissue markers are placed around the residual cavity formed after breast surgery to act as radiation tracking markers, making radiation more precise and consolidating treatment. Xinke Medical is currently preparing to build another breast tissue marker production line with an annual production capacity of 100,000 sets in the life science acceleration zone of Jiangning High-tech Zone.

Yangtze Evening News/Ziniu News reporter Liu Liyuan Jiang Jingyi Xu Yuanyuan

Proofreader Xu Heng